Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines
December 5, 2019 8:02 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown)... More
After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)
December 3, 2019 6:02 PM ESTAfter-Hours Movers
HealthEquity (NASDAQ: HQY) 12.7% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.
Revance Therapeutics, Inc. (Nasdaq: RVNC) 10.7% LOWER; announced a proposed underwritten public offering of its common stock. The Company intends to use the net... More
Goldman Sachs Starts Revance Therapeutic (RVNC) at Buy
December 2, 2019 4:30 AM ESTGoldman Sachs analyst Terence Flynn initiates coverage on Revance Therapeutic (NASDAQ: RVNC) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Revance Therapeutic click here. For more ratings news on Revance Therapeutic click here.
Shares of Revance Therapeutic closed at $17.90 yesterday.
... More